Risk factors for the development and characteristics of cognitive dysfunction in patients with a history of COVID-19 infection

Risk factors for the development and characteristics of cognitive dysfunction in patients with a history of COVID-19 infection

 

Authors

 

M.F.Belokrylova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

V.B. Nikitina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

V.A. Rudnitsky

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

V.S. Maltsev

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

O.V. Sazonova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

M.G. Vasilieva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

A.A. Ivanova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

E.V. Tsybulskaya

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

V.F. Lebedeva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

O.A. Pavlova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

T.V. Kazennykh

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

N.P. Garganeeva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

O.E. Perchatkina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

N.A. Bokhan

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-4(129)-71-83

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 4 (129):  71-83.

 

Abstract

Background. Regardless of the severity of COVID-19 and the duration of the post-COVID period, patients continue to complain of cognitive dysfunction, the onset of which coincided with the active phase of the infection. Objective. To study the risk factors for cognitive dysfunction and the characteristics of cognitive impairment in patients who have had COVID-19. Materials and Methods. A comprehensive examination of 48 patients (8 men and 40 women) with nonpsychotic mental disorders in the form of cognitive dysfunction and asthenic disorders diagnosed in the post-COVID period was conducted at the First Clinical Psychiatric Unit of the Mental Health Research Institute of the Tomsk National Research Medical Center. The following methods were used: clinical-psychopathological, physical, psychological, clinical-laboratory, instrumental, and statistical. To determine cognitive resources, the following tests were used: Schulte tables, the Method of memorizing 10 words according to A.R. Luria. State anxiety was assessed using the Spielberger-Khanin State Anxiety Assessment Method. Results.A feature of the psychodiagnostic examination of patients was the presence of more than two comorbidities of internal organs and other pathological conditions, i.e., polymorbidity, which is an unfavorable background for overcoming a viral infection. In 68.75% of patients, COVID-19 was mild, but a decrease in cognitive functioning remained. Regardless of the severity of COVID-19, patients did not differ significantly in age, polymorbidity index, level of state anxiety, the results of the methods performed to assess cognitive functions (attention, memory). At the time of the examination, patients had difficulty concentrating on the meaning of a task for a long time, could keep a limited number row in memory, without noticing or correcting errors. Work efficiency, degree of warming-up and mental stability; “exhaustion curve” and “memory curve” were analyzed as well as the relationship between cognitive functioning indices and state anxiety. The lowest cognitive resource was noted in the group of men suffering from heart rhythm disorders and chronic obstructive pulmonary disease. Women with hypothyroidism showed good ability to work on tasks, but reduced resistance to stress during task completion. Direct correlations were found be-tween the state anxiety indicator after treatment and the time required to complete the task when working with Schulte tables (R=0.310, p=0.031875 – Table 3; R=0.350, p=0.014573 – Table 5). Conclusion.Analysis of risk factors for the development of cognitive impairment showed that in the presence of high polymorbidity indices, individual conditions and diseases cause statistically significant differences compared to their absence, affecting the mental health and performance of patients with cerebral disorders exhibiting cognitive dysfunction. The diversity and ambiguity of the revealed relationships require a differentiated approach to diagnosis and therapeutic tactics in the management of patients with complaints of cognitive dysfunction in the structure of organic nonpsychotic disorders with polymorbid somatic pathology.

 

Keywords: nonpsychotic mental disorders, cognitive dysfunction, coronavirus infection, polymorbidity, situational anxiety.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Belokrylova M.F., Nikitina V.B., Rudnitsky V.A., Maltsev V.S., Sazonova O.V., Vasilieva M.G., Ivanova A.A., Tsybulskaya E.V., Lebedeva V.F., Pavlova O.A., Kazennykh T.V., Garganeeva N.P., Perchatkina O.E., Bokhan N.A. Risk factors for the development and characteristics of cognitive dysfunction in patients with a history of COVID-19 infection. Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 4 (129): 71-83. https://doi.org/10.26617/1810-3111-2025-4(129)-71-83

 

REFERENCES

  1. Galkin SA, Peshkovskaya AG, Ivanova SA, Bokhan NA. Cognitive impairment in patients who have had COVID-19. Yakut Medical Journal. 2021;1(73):69-72. https://doi.org/10.25789/YMJ.2021.73.19 (in Russian).
  2. Pizova NV, Pizov NA, Pizov AV. Cognitive impairment in COVID-19 survivors. Medical Council. 2021;4:69-77. https://doi.org/10.21518/2079-701X-2021-4-69-77 (in Russian).
  3. Kabysh SS, Karpenkova AD, Prokopenko SV, Golikova-Chereshkevich AV, Narkevich AN. Cognitive functions during acute period of COVID-19 and recovery. Doctor.Ru. 2022;21(4):43-46. https://doi.org/10.31550/1727-2378-2022-21-4-43-46(in Russian).
  4. Manfredini A, Pisano F, Incoccia C, Marangolo P. The impact of COVID-19 lockdown measures and COVID-19 infection on cognitive functions: a review in healthy and neurological populations. Int J Environ Res Public Health. 2023 Mar 10; 20(6):4889. https://doi.org/10.3390/ijerph20064889. PMID: 36981800.
  5. Zawilska JB, Kuczyńska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res. 2022 Dec;156:349-360. https://doi.org/10.1016/j.jpsychires. 2022.10.045. Epub 2022 Oct 20. PMID: 36326545;
  6. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, Rodrigues NB, Subramaniapillai M, Di Vincenzo JD, Cao B, Lin K, Mansur RB, Ho RC, Rosenblat JD, Miskowiak KW, Vinberg M, Maletic V, McIntyre RS. Fatigue and cognitive impairment in post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022 Mar;101:93-135. https://doi.org/10.1016/j.bbi.2021.12.020. Epub 2021 Dec 29. PMID: 34973396; PMCID: PMC8715665.
  7. Dvoretsky LI, Komarova IS, Mukhina NV, Cherkasova NA, Dyatlov NV. Novel coronavirus infection (COVID-19) in elderly and senile patients. Medical Bulletin of the North Caucasus. 2022;17(3):335-341.https://doi.org/10.14300/mnnc.2022.17082(in Russian).
  8. Generalova LV, Burgasova OA, Kolobukhina LV, Tetova VB, Gushchin VA, Melkonyan GG, Generalov EA. COVID-19: Clinical characteristics and outcomes depending on comorbid pathology. Bashkortostan Medical Journal. 2022;17,3(99):15-19 (in Russian).
  9. Shcherbak SG, Sarana AM, Anisenkova AYu, Vologzhanin DA, Golota AS, Kamilova TA. The influence of comorbidities on the severity of COVID-19. University Therapeutic Journal. 2024;6(1):26-48. https://doi.org/10.56871/UTJ.2024.35.52.003 (in Russian).
  10. Korostovtseva LS, Rotar OP, Konradi AO. COVID-19: What are the risks in hypertensive patients? Arterial Hypertension. 2020;26(2):124-132.https://doi.org/10.18705/1607-419X-2020-26-2-124-132 (in Russian).
  11. Sharvadze GG, Mamedov MN. Risk groups during the COVID-19 epidemic: Focus on the kidneys and reproductive system. Russian Journal of Preventive Medicine. 2020;23(7):85-90. https://doi.org/10.17116/profmed20202307185 (in Russian).
  12. Khokhlova AV, Boichenko PK, Parkhomchuk DS, Vostrikov AA. COVID-19 in persons with diabetes mellitus and obesity in a cluster of metabolic syndrome. Pathological Physiology and Experimental Therapy. 2021;65(1):102-106. https://doi.org/10.25557/0031-2991.2021.01.102-106 (in Russian).
  13. Kulikov VD, Sukhovskaya OA, Smirnova MA, Kuzubova NA, Titova ON. Chronic obstructive pulmonary diseases as a risk factor for severe COVID-19 (review). Pediatrician. 2022;13(4):75-82. https://doi.org/10.17816/PED13475-82 (in Russian).
  14. Evsyutina YuV, Danilov AB, Filatova EG, Simonova AV. Clinical and neurospychological patterns of ongoing symptomatic COVID-19 and post COVID syndrome. Russian Medical Journal. 2024;4:30-35 (in Russian).
  15. Golovacheva VA, Tabeeva GR, Kuznetsov IV. Cognitive impairment in COVID-19: Associations, pathogenesis and treatment questions. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):123-129.https://doi.org/10.14412/2074-2711-2021-2-123-129(in Russian).
  16. Oganov RG, Simanenkov VI, Bakulin IG, Bakulina NV, Barbarash OL, Boytsov SA, Boldueva SA, Garganeeva NP, Doshchitsin VL, Karateev AE, Kotovskaya YuV, Lila AM, Lukyanov MM, Morozova TE, Pereverzev AP, Petrova MM, Pozdnyakov YuM, Syrov AV, Tarasov AV, Tkacheva ON, Shalnova SA. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. http://dx.doi.org/10.15829/1728-8800-2019-1-5-66(in Russian).
  17. OganovRG, DrapkinaOM. Polymorbidity: specifics of co-development and concomitance of several diseases in one patient. Cardiovascular Therapy and Prevention. 2016;15(4):4-9.https://doi.org/10.15829/1728-8800-2016-4-4-9(in Russian).